Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF), the drug repurposing firm, told investors it has enrolled its first patient from the US for its multinational Phase 2b/3 human study of Ifenprodil to treat coronavirus (COVID-19).
"We are very pleased to announce our first U.S. patient,” said Christopher J. Moreau, the chief executive of the Vancouver-based company said in a statement. "We have also had steady enrollment from one of our International sites and as a result, we expect to reach 25% of our total target shortly."
READ: Algernon says first patient dosed in Phase 2 study of Ifenprodil as a treatment in idiopathic pulmonary fibrosis and chronic cough
That target is 150 patients from all participating sites and so far, the firm has enrolled 26 since the study began on August 5 this year.
The trial will begin as a Phase 2b study of 150 patients and will move directly into a Phase 3 trial if preliminary data is positive. The data from the Phase 2b will determine the number of patients needed to reach statistical significance in the Phase 3 study.
Algernon believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively.
The latter can result in the so-called cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in coronavirus (COVID-19) infected patients.
Contact the author at email@example.com